Validation of the SPF10 LiPA human papillomavirus typing assay using formalin-fixed paraffin-embedded cervical biopsy samples

Journal of Clinical Microbiology

Volumn 47, Issue 7, 2009, Pages 2175-2180

  Dal Bello, Barbara ^a   Spinillo, Arsenio ^a   Alberizzi, Paola ^a   Cesari, Stefania ^a   Gardella, Barbara ^a   Silini, Enrico Maria ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 42; HUMAN PAPILLOMAVIRUS TYPE 43; HUMAN PAPILLOMAVIRUS TYPE 44; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUNCH BIOPSY; SPF10 LIPA HUMAN PAPILLOMAVIRUS TYPING ASSAY; UTERINE CERVIX BIOPSY; VALIDATION PROCESS; VIRUS TYPING; WART VIRUS; BIOPSY; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; EVALUATION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; PAPILLOMA VIRUS; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION; UTERINE CERVIX; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADULT; BIOPSY; CERVIX UTERI; FEMALE; FORMALDEHYDE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PARAFFIN EMBEDDING; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION;

EID: 67650092754     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00286-09     Document Type: Article

References (32)

1. Reference deleted.
2. Baay, M. F., W. G. Quint, J. Koudstaal, H. Hollema, J. M. Duk, M. P. Burger, E. Stolz, and P. Herbrink. 1996. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J. Clin. Microbiol. 34:745-747.
3. Bosch, F. X., A. N. Burchell, M. Schiffman, A. R. Giuliano, S. de Sanjose, L. Bruni, G. Tortolero-Luna, S. K. Kjaer, and N. Munoz. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl. 10):K1-K16.
4. Castle, P. E., P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman. 2008. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J. Clin. Microbiol. 46:109-117.
5. Castle, P. E., D. Solomon, M. Schiffman, and C. M. Wheeler. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical pre-cancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97:1066-1071.
6. Chan, P. K., T. H. Cheung, A. O. Tam, K. W. Lo, S. F. Yim, M. M. Yu, K. F. To, Y. F. Wong, J. L. Cheung, D. P. Chan, M. Hui, and M. Ip. 2006. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int. J. Cancer 118:243-245.
7. Dal Bello, B., A. Spinillo, P. Alberizzi, S. Cesari, B. Gardella, G. D'Ambrosio, M. Roccio, and E. M. Silini. 2009. Cervical infections by multiple human papillomavirus (HPV) genotypes: prevalence and impact on the risk of precancerous epithelial lesions. J. Med. Virol. 81:703-712.
8. Fleiss, J. L., B. Levin, and M. C. Paik. 2003. Statistical methods for rates and proportions, 3rd ed. John Wiley & Sons, New York, NY.
9. Food and Drug Administration. 2001. FDA vaccines and related biological products advisory committee, meeting 88 report. Center for Biologics Evaluation and Research, Food and Drug Administration, Washington, DC.
10. Gravitt, P. E., F. Coutlee, T. Iftner, J. W. Sellors, W. G. Quint, and C. M. Wheeler. 2008. New technologies in cervical cancer screening. Vaccine 26(Suppl. 10):K42-K52.
11. Gravitt, P. E., L. J. van Doorn, W. Quint, M. Schiffman, A. Hildesheim, A. G. Glass, B. B. Rush, J. Hellman, M. E. Sherman, R. D. Burk, and S. S. Wang. 2007. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J. Clin. Microbiol. 45:3245-3250.
12. IARC Working Group on the Evaluation of Cancerogenic Risks to Humans. 2005. IAEC monographs on the evaluation of carcinogenic risks to humans, vol. 90. Human papillomaviruses. International Agency for Research on Cancer, Lyon, France.
13. Iftner, T., and L. L. Villa. 2003. Human papillomavirus technologies. J. Natl. Cancer Inst. Monogr. 31:80-88.
14. Karlsen, F., M. Kalantari, M. Chitemerere, B. Johansson, and B. Hagmar. 1994. Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation. Lab. Investig. 71:604-611.
15. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
16. Kleter, B., L. J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. ter Schegget, J. Lindeman, B. ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517.
17. Kleter, B., L. J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, B. ter Harmsel, and W. Quint. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739.
18. Klug, S. J., A. Molijn, B. Schopp, B. Holz, A. Iftner, W. Quint, P. J. F. Snijders, K. U. Petry, S. Kruger Kjaer, C. Munk, and T. Iftner. 2008. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J. Med. Virol. 80:1264-1274.
19. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, and K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
20. Kovacic, M. B., P. E. Castle, R. Herrero, M. Schiffman, M. E. Sherman, S. Wacholder, A. C. Rodriguez, M. L. Hutchinson, M. C. Bratti, A. Hildesheim, J. Morales, M. Alfaro, and R. D. Burk. 2006. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 66:10112-10119.
21. Matsukura, T., and M. Sugase. 2008. Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int. J. Gynecol. Cancer 18:1042-1050.
22. Meijer, C. J., P. J. Snijders, and P. E. Castle. 2006. Clinical utility of HPV genotyping. Gynecol. Oncol. 103:12-17.
23. Munoz, N., F. X. Bosch, X. Castellsague, M. Diaz, S. de Sanjose, D. Hammouda, K. V. Shah, and C. J. Meijer. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111:278-285.
24. Muñoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
25. Perrons, C., R. Jelley, B. Kleter, W. Quint, and N. Brink. 2005. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J. Clin. Virol. 32:278-285.
26. Quint, W. G., G. Scholte, L. J. van Doorn, B. Kleter, P. H. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J. Pathol. 194:51-58.
27. 10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J. Clin. Microbiol. 45:1447-1454.
28. Snijders, P. J., A. J. van den Brule, and C. J. Meijer. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 201:1-6.
29. Stanley, M. 2006. Immune responses to human papillomavirus. Vaccine 24(Suppl. 1):S16-S22.
30. van Doorn, L.-J., A. Molijn, B. Kleter, W. Quint, and B. Colau. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44:3292-3298.
31. 10 line probe assay. J. Clin. Microbiol. 40:979-983.
32. 10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche Linear Array HPV genotyping test. J. Clin. Microbiol. 44:3122-3129.